Kelisha capsule alleviates dextran sulfate sodium-induced acute colitis alongside changes in gut microbiota and PI3K/AKT phosphorylation

Background Kelisha capsule (KLS) is a licensed Chinese patent medicine for diarrhea and related gastrointestinal disorders, yet its activity in noninfectious colonic injury remains incompletely defined. Methods Three production batches were compared qualitatively by chromatography using borneol, eugenol, and piperine as markers. Batch 240506 was tested in male mice with dextran sulfate sodium (DSS)-induced acute colitis. Disease activity, histology, circulating cytokines, and tight-junction proteins were assessed. Fecal 16S rRNA gene sequencing and colonic RNA sequencing included Control, DSS, and high-dose KLS groups. Ereg mRNA and phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) phosphorylation were examined by qPCR and immunoblotting, respectively. Donor fecal material transfer and YS49 coadministration during transfer or Akkermansia muciniphila administration were also evaluated. Results Chromatography showed qualitative concordance of the three markers. High-dose KLS improved disease activity, mucosal injury, and cytokine profiles and increased Occludin and Claudin-1 abundance. Treatment was accompanied by partial recovery of microbial diversity, an exploratory genus-level Akkermansia association, lower Ereg mRNA, and reduced p-PI3K/PI3K and p-AKT/AKT ratios. Recipients of KLS-treated donor material showed improved outcomes and a similar molecular pattern. YS49 coadministration was associated with higher phosphorylation ratios and worse outcomes. Conclusion KLS alleviated acute DSS colitis alongside microbial changes, lower Ereg mRNA, and reduced PI3K/AKT phosphorylation. These findings support its preclinical pharmacological activity and identify microbial and host responses for further mechanistic investigation.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-16
DOI
https://doi.org/10.3389/fphar.2026.1969287
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Kelisha capsule alleviates dextran sulfate sodium-induced acute colitis alongside changes in gut microbiota and PI3K/AKT phosphorylation

Jieya Chen, Yu Song, Yingzi Hu, Jin Wu et al.
2 links
Frontiers in Pharmacology
Inflammatory Bowel Disease
article

Kelisha capsule alleviates dextran sulfate sodium-induced acute colitis alongside changes in gut microbiota and PI3K/AKT phosphorylation

Jieya Chen, Yu Song, Yingzi Hu, Jin Wu, Guilin Ren, Shihui Wang, Xia Liu, Shiyu Gao, Zhenhui Zhang, Yingchao Liu
article en

Abstract

Background Kelisha capsule (KLS) is a licensed Chinese patent medicine for diarrhea and related gastrointestinal disorders, yet its activity in noninfectious colonic injury remains incompletely defined. Methods Three production batches were compared qualitatively by chromatography using borneol, eugenol, and piperine as markers. Batch 240506 was tested in male mice with dextran sulfate sodium (DSS)-induced acute colitis. Disease activity, histology, circulating cytokines, and tight-junction proteins were assessed. Fecal 16S rRNA gene sequencing and colonic RNA sequencing included Control, DSS, and high-dose KLS groups. Ereg mRNA and phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) phosphorylation were examined by qPCR and immunoblotting, respectively. Donor fecal material transfer and YS49 coadministration during transfer or Akkermansia muciniphila administration were also evaluated. Results Chromatography showed qualitative concordance of the three markers. High-dose KLS improved disease activity, mucosal injury, and cytokine profiles and increased Occludin and Claudin-1 abundance. Treatment was accompanied by partial recovery of microbial diversity, an exploratory genus-level Akkermansia association, lower Ereg mRNA, and reduced p-PI3K/PI3K and p-AKT/AKT ratios. Recipients of KLS-treated donor material showed improved outcomes and a similar molecular pattern. YS49 coadministration was associated with higher phosphorylation ratios and worse outcomes. Conclusion KLS alleviated acute DSS colitis alongside microbial changes, lower Ereg mRNA, and reduced PI3K/AKT phosphorylation. These findings support its preclinical pharmacological activity and identify microbial and host responses for further mechanistic investigation.

Frontiers in PharmacologyVol. 17
Zhejiang Chinese Medical University (CN)
Good health and well-being
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon